The following stories appear in full on Today's Vidyya Medical News Service Web site.
The Food and Drug Administration (FDA) announced the approval of two new drugs to treat the elevated intraocular pressure which is often associated with glaucoma - Lumigan (bimatoprost ophthalmic solution) 0.03% and Travatan (travoprost ophthalmic solution) 0.004%. They will provide additional alternatives for the reduction of intraocular pressure in patients who are intolerant of other intraoular lowering medications, or in patients who have had insufficient responses to other intraocular pressure lowering medications. Many of these patients might otherwise need surgery for management of their glaucoma.
For more information: FDA Approves Two New Intraocular Pressure Lowering Drugs For The Management Of Glaucoma
Neural tube defects (NTDs), which include spina bifida and anencephaly, are serious malformations that occur in the developing fetus during the first 17--30 days after conception. Consumption of supplements containing folic acid can reduce NTDs 50%--70%. In the United States, approximately 4000 pregnancies are affected by NTDs each year. In 1992, the US Public Health Service recommended that all women of childbearing age consume at least 400 µg of folic acid daily. In 1998, the Institute of Medicine reaffirmed that recommendation and added that women capable of becoming pregnant take 400 µg of synthetic folic acid daily from fortified foods and/or supplements and consume a balanced, healthy diet of folate-rich foods. Recent findings suggest that public health campaigns that promote the consumption of folic acid should target women who are young, unmarried, obese, smoke, eat few fruits and vegetables, and have a low level of education.
For more information: Despite Advertising And Education, Women Still Unaware Of The Importance Of Folic Acid
Eclipse Surgical Technologies, a medical device company specializing in cardiac angiogenesis, announced today that promising data from a randomized
double-blinded independent assessment study of the company's minimally-invasive laser heart procedure, Percutaneous Transmyocardial Revascularization (PTMR), for treating advanced cardiovascular disease is being presented at the annual American College of Cardiology (ACC) conference
in Orlando, Fla. March 18-21.
For more information: Information On New Laser Heart Treatment Presented At ACC Conference
Results from an analysis of the MARISA trial demonstrates that patients with both chronic angina and a history of congestive heart failure (CHF) tolerate and respond to ranolazine at least as well as angina patients without CHF. At trough plasma concentrations, ranolazine produced statistically significant (p< 0.001) increases in exercise duration, time to angina and time to 1 mm ST segment depression compared to placebo in the angina patients without CHF. Statistically similar increases were observed at trough in the angina patients with CHF. Furthermore, at peak ranolazine plasma concentrations, patients with CHF had increases in exercise duration and time to 1 mm ST segment depression compared to placebo which were significantly greater (p < 0.01) than those observed in the patients without CHF.
For more information: Ranolazine Of Potential Benefit To Patients With Both Chronic Angina And CHF
Physical activity on the job should be good for a person's blood vessels--unless the job has a lot of stress, which can cancel the activity's value, a study indicates. Another expert, however, considers that conclusion provocative but not yet proved.
For more information: Stress Offsets Benefits Of Hard, Physical Labor
Today's Vidyya articles are:
As always, we hope you enjoy the issue.